MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
1.870
+0.010
+0.54%
Opening 10:34 05/07 EDT
OPEN
1.910
PREV CLOSE
1.860
HIGH
1.960
LOW
1.861
VOLUME
48.37K
TURNOVER
--
52 WEEK HIGH
8.23
52 WEEK LOW
1.310
MARKET CAP
132.69M
P/E (TTM)
-1.1666
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NKTX last week (0428-0502)?
Weekly Report · 2d ago
Weekly Report: what happened at NKTX last week (0421-0425)?
Weekly Report · 04/28 09:30
Weekly Report: what happened at NKTX last week (0414-0418)?
Weekly Report · 04/21 09:30
Weekly Report: what happened at NKTX last week (0407-0411)?
Weekly Report · 04/14 09:28
FDA staff cuts are already impacting regulatory work, Biotech leaders warn
Seeking Alpha · 04/10 15:37
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)
TipRanks · 04/09 10:30
Weekly Report: what happened at NKTX last week (0331-0404)?
Weekly Report · 04/07 09:28
Nkarta to Participate in an April Investor Conference
Barchart · 04/01 07:01
More
About NKTX
More
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Recently
Symbol
Price
%Change

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.